MALIRID
Brand:
MALIRID
Manufacturer:
IPCA
Manufacturer Details
IPCA
Compositions:
Primaquine phosphate 7.5mg/15mg F.C.tablets,
Primaquine phosphate 45mg tablets,
|
Strength
|
Rate
|
Packing Style
|
|
7.5mg F.C.. tabs.
|
16.62
|
7s F.C. tablets
|
|
15mg F.C.
|
35.12
|
7s F.C.s tabs-
|
|
45mg
|
31.50
|
10s tablets
|
List of Related Indications:
- Malaria resistent to others
List Of Drugs:
- Primaquine Phosphate @ - 8- Aminoquinoline compound
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Drug interactions -summary-
- Primaquine +
Antimalarial compd- quinacrine may potentiate toxicity of antimalarial compounds which Qunacrine are structurally related . Do not administer primaquine to patients who have recently received quinacrine.
Adverse Reaction:
Nausea, vomiting, epigastric distress, abdominal cramps. Leucopenia, hemolytic anemia in G6PD deficient individuals, Methemoglobenia in NADH methemoglobin reductase deficient individuals.
Contra-Indications:
Concomittant administration of quinacrine and primaquine on the acutely ill suffering from
systemic disease manifested by tendency to granulocytopenia (eg. rheumatoid arthiritis and lupus erythematosus) ; concomittant administration of potentially hemolytic drugs or bone marrow depressants.
Warning:
Hemolytic reactions may occur in following group of people while receiving primaquine:
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency patients or in individuals with
idiosyncratic reactions, or individuals with nicotinamide adenine dinucleotide(NADH)
methemoglobin reductase deficiency.
Discontinue if marked darkening of the urine or sudden decrease in hamoglobin concentration or leukocyte count occurs.
Pregnancy: Safety for use during pregnancy has not ben established. Use only when clearly needed and when potential benefits outweigh potential hazards to the fetus.
Special precautions:
Anemia,methomoglobinemia and leukopenia . Perform routine blood examinations. during
therapy.
Dosages/ Overdosage Etc:
Malaria
Dosage:
Begin therapy during the last 2 weeks of or , following a course of, supression with chloroquine or a comparable drug.
Adults- 26.3mg(15mg base) daily for 14 days. Children- 0.5mg/kg/day(0.3mg base/ kg/day; maximum 15mg base/dose) for 14 days.
Patient Information:
1.Discontinue if marked darkening of the urine or sudden decrease in hemoglobin
concentration or leukocyte count occurs.
2.Complete full course of therapy
3. If GI upset occurs, may be taken with food. If stomach upset(nausea, vomiting, or stomach
pain) continues, notify physician.
4. Notify physician, if darkening of urine occurs.
5. Perfom routine blood examinations (particularly blood cell counts and haemoglobin
determinations), during pregnancy.
Pharmacology/ Pharmacokinetics:
Pharmacology:
An 8-aminoquinoline, primaquine is structurally similar to the 4-aminoquinolines but possesses markedly different antimalarial activities. Primaquine may disrupt the parasites mitochondria and bind a native DNA . The resulting structural changes create a major distruption in the metabolic process.
Pharmacokinetics:
After oral administration, peak plasma concentrations of primaquine are reached in 1 to 3 hours. Primaquine is rapidly metabolised to a carboxylic acid derivative and then to further metabolites which have varying degrees of activity. The elimination half-life is 4 hours.
Interaction with Food:
If GI upset occurs, may be taken with food.
Pregnancy and lactation:
Pregnancy:
Safety for use during pregnancy has not ben established. Use only when clearly needed and when potential benefits outweigh potential hazards to the fetus.
